Serum trypsinogen-2 and trypsin-2-α1-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas
✍ Scribed by Johan Hedström; Caj Haglund; Reijo Haapiainen; Ulf-Håkan Stenman
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- French
- Weight
- 527 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Serum concentrations of trypsinogen-2 and trypsin-2-a,antibypsin (trypsin-2-AAT) were determined in I45 patients with malignant and 61 with benign digestive-tract diseases. The validity of these tests for detection of cancer was compared with that of CA19-9 and CEA. Elevated levels of trypsinogen-2 (>90 pgh) and trypsin-t-AAT (>25 pg/I) were found in 46% and 42%, respectively, of patients with malignant disease and the levels of trypsinogen-2 were significantly higher than in those with benign disease (p < 0.005). High trypsinogen-2 and trypsin-2-AAT concentrations were found most often in patients with biliary and pancreatic cancer, but also in benign obstructive biliary disease. Our results suggest that trypsinogen-2 and trypsin-2-AAT are new potential markers for cholangiocarcinomas.